NCT07644351已完成不适用
Asciminib Effectiveness in Real World Setting of Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL); a Retrospective Review Study of Patients From the Asciminib Managed Access Program (ASCERTAIN)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 18
研究概览
简要总结
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients enrolled in the asciminib MAP.
- •Diagnosis of Ph+ ALL.
- •Patients received at least one dose of asciminib through the asciminib MAP.
- •Appropriate approval obtained for the use of patient data including:
- •Signed informed consent form (ICF), or
- •ICF waiver granted by an Institutional review board/Independent Ethics Committee (IRB/IEC).
排除标准
- •Age < 18 years at the time of initiating asciminib treatment.
研究者
研究点 (18)
Loading locations...
相似试验
尚未招募
不适用
Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent LinesNCT07640750Gruppo Italiano Malattie EMatologiche dell'Adulto98
招募中
2 期
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia.2023-508129-28-00Novartis Pharma AG17
招募中
1 期
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)Acute Lymphoblastic LeukemiaNCT07387926Novartis Pharmaceuticals50
招募中
不适用
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyLeukemia, Chronic MyeloidNCT07549516Novartis Pharmaceuticals380
招募中
2 期
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPChronic Myelogenous LeukemiaNCT07354074Novartis Pharmaceuticals50